Mexiprim solution for injection 50mg/ml 2ml 10 pcs

Compound

There are two main forms of release of this drug - injections and tablets, the composition of which differs from each other in the amount of ethylmethylhydroxypyridine succinate .
One milliliter of Mexiprim solution contains 50 grams of the active drug compound, as well as about 1 milliliter of an excipient - water for injection.

One film-coated Mexiprim tablet contains 0.125 grams of ethylmethylhydroxypyridine succinate , as well as excipients such as talc, kaolin, povidone, sodium carboxymethyl starch, calcium stearate and MCC.

The shell of the tablet form of the drug contains compounds such as talc, hypromellose, titanium dioxide, and macrogol.

Release form

As mentioned earlier, the drug is produced in the form of round tablets, biconvex in shape and coated with a specialized white or cream-colored coating, as well as in the form of an injection solution, which is a transparent liquid of colorless or pale yellow color.

The nominal weight of one tablet is 125 mg. The tablets are packaged in blisters (cell-shaped made of aluminum foil and PVC) of 10 pcs. in everyone. One cardboard package can contain 1,2,3,4, 6 blisters.

The solution intended for the preparation of injections is packaged in ampoules of 2 or 5 ml. in each and placed in contour cells. One cardboard package may contain 20, 50 or 100 ampoules complete with a special knife for opening them.

Mexiprim - description and action

The drug Mexiprim is an antioxidant drug, the active substance is ethylmethylhydroxypyridine succinate. This component is a free radical inhibitor, a membrane protector, with the following actions:

• anticonvulsant;
• nootropic;
• neuroprotective;
• antihypoxic;
• sedative;
• stress-protective.

Mexiprim is available in different dosage forms. Tablets 0.125 mg contain the indicated amount of the main substance, as well as additional components - talc, macrogol, titanium dioxide, cellulose, povidone, etc. In packs of 30.60 tablets, the price for a small package is 210 rubles

. Mexiprim solution is produced in ampoules of 2 and 5 ml, in boxes of 5, 10, 15 ampoules. Contains active substance and water for injection.

When used as a course of treatment, the medicine gives the following effects:

• optimizes metabolism in brain tissue;
• improves blood supply to brain cells;
• improves blood quality, saturates it with oxygen and reduces hypoxia;
• reduces platelet aggregation processes;
• stabilizes the cell membranes of red blood cells and other blood elements;
• reduces cholesterol levels;

• increases the body's resistance to stress;
• improves performance, attentiveness;
• reduces the effects of alcohol.

After oral administration in tablet form, maximum concentration is achieved within 30 minutes. The period of complete elimination from the body is 8-12 hours.

WE RECOMMEND THE ARTICLE!

Betahistine helps against neurological diseases when headaches and dizziness occur. Read more >>

Pharmacodynamics and pharmacokinetics

Since this drug belongs to the heteroaromatic antioxidant series , Mexiprim is distinguished by its wide range of applications. The medicine increases the body's resistance to stressful situations. When using the drug, its anxiolytic properties , without muscle relaxant effects or drowsiness .

In addition, the drug reduces and prevents the occurrence of memory and learning disorders , and has a nootropic and anticonvulsant effect on elderly patients. Thanks to its antihypoxic and antioxidant properties, Mexiprim helps improve performance and concentration, and in addition, minimizes the harmful toxic effects of alcoholic beverages.

Mexiprim has a positive effect on brain tissue, as well as the body’s circulatory system by stimulating blood microcirculation and platelet aggregation . The drug reduces cholesterol due to its pronounced lipid-lowering abilities . When the drug enters the human body, it is rapidly metabolized and transformed into glucurone-conjugated breakdown products .

Indications for use of Mexiprim

General indications for use for the two main forms of the drug are the following conditions and diseases:

• vegetative-vascular dystonia;
• withdrawal syndrome accompanied by vegetative-vascular and neurosis-like disorders in alcoholism ;
• nervous disorders;
• cognitive disorders in asthenic and psychoorganic syndrome caused by intoxication , circulatory disorders in the brain, neuroinfections, atrophic or senile processes ;
• exposure to stress ;
• disorders of intelligence and memory in elderly patients.

Mexiprim injection solution is also used for cerebral circulatory (acute forms), for cognitive disorders caused by atherosclerotic genesis , and in addition, for dyscirculatory encephalopathy.

Mexiprim

An inhibitor of free radical processes is a membrane protector, which also has antihypoxic, stress-protective, nootropic, antiepileptic and anxiolytic effects. Belongs to the class of 3-hydroxypyridines.

The mechanism of action is due to antioxidant and membrane protective properties. Suppresses lipid peroxidation, increases superoxide oxidase activity, increases the lipid-protein ratio, improves the structure and function of the cell membrane. Modulates the activity of membrane-bound enzymes (Ca2+-independent PDE, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which promotes their binding to ligands, preservation of the structural and functional organization of biomembranes, transport of neurotransmitters and improvement of synaptic transmission. Increases the concentration of dopamine in the brain.

Ethylmethylhydroxypyridine succinate enhances the compensatory activation of aerobic glycolysis and reduces the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in ATP and creatine phosphate, and activates the energy-synthesizing function of mitochondria.

Increases the body's resistance to the effects of various damaging factors in pathological conditions (shock, hypoxia and ischemia, cerebrovascular accidents, intoxication with ethanol and antipsychotic drugs).

Ethylmethylhydroxypyridine succinate improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, and reduces platelet aggregation. Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. It has a lipid-lowering effect, reduces the content of total cholesterol and LDL.

Improves the functional state of ischemic myocardium during myocardial infarction, the contractile function of the heart, and also reduces the manifestations of systolic and diastolic dysfunction of the left ventricle.

In conditions of a critical decrease in coronary blood flow, it helps to preserve the structural and functional organization of cardiomyocyte membranes, stimulates the activity of membrane enzymes - PDE, adenylate cyclase, acetylcholinesterase. Supports the activation of aerobic glycolysis that develops during acute ischemia and promotes the restoration of mitochondrial redox processes under hypoxic conditions, increases the synthesis of ATP and creatine phosphate. Ensures the integrity of the morphological structures and physiological functions of the ischemic myocardium.

Ethylmethylhydroxypyridine succinate improves the clinical course of myocardial infarction, increases the effectiveness of therapy, accelerates the restoration of functional activity of the LV myocardium, reduces the incidence of arrhythmias and intracardiac conduction disorders.

Normalizes metabolic processes in the ischemic myocardium, reduces the necrosis zone, restores and/or improves the electrical activity and contractility of the myocardium, and also increases coronary blood flow in the ischemic zone, increases the antianginal activity of nitro drugs, improves the rheological properties of blood, reduces the consequences of reperfusion syndrome in acute coronary insufficiency.

Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

Contraindications

General contraindications for both injections and Mexiprim tablets are:

• pregnancy;
• childhood;
• hypersensitivity;
• lactation period;
• disorders of the liver or kidneys (acute stages of the disease).

The tablet form of the drug is not recommended for use in case of renal or liver failure .

Instructions for use of Mexiprim (Method and dosage)

The instructions for use of Mexiprim tablets prescribe taking them orally 2-3 times a day in a dosage individually determined by the doctor, for each individual patient, taking into account all physiological characteristics. It is recommended to start using the drug with a dosage of 0.25-0.5 grams. The maximum average daily dose of the drug should not exceed 0.8 grams.

The duration of the therapeutic course of treatment with the drug, depending on the type and severity of the patient’s disease/condition, can vary from 5 days to 6 weeks. It is recommended to reduce the dosage of the drug gradually over the last 2-3 days of the course of treatment.

Mexiprim injections are administered intramuscularly or intravenously (drip or jet) 1-3 times a day. The dosage of the drug is determined individually, taking into account the characteristics of each specific case. When administering an injection solution by infusion, the drug is diluted with sodium chloride. As a rule, the dosage of the first injections does not exceed 100 mg. Subsequently, the dose of the drug is gradually increased.

The duration of the therapeutic course of treatment with Mexiprim injection solution also depends on the patient’s condition and the severity of the disease; it can last from 7 to 30 days.

Mexiprim solution for injection 50mg/ml amp 5ml N 15

Release form, composition.

Mexiprim solution for intravenous and intramuscular administration
1 ml:

— ethylmethylhydroxypyridine succinate 50 mg

excipients: water for injection.

Pharmgroup:

antioxidant agent.

Pharmaceutical action:

Mexiprim® is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body's resistance to the effects of various damaging factors (shock, hypoxia and ischemia, cerebrovascular accidents, intoxication with alcohol and antipsychotics (neuroleptics).

The mechanism of action of Mexiprim® is due to its antioxidant and membrane protective effect. It inhibits lipid peroxidation, increases superoxide oxidase activity, increases the lipid-protein ratio, reduces membrane viscosity, and increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improve synaptic transmission. Mexiprim® increases the level of dopamine in the brain. Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.

The drug improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a lipid-lowering effect, reduces the content of total cholesterol and LDL.

Pharmacokinetics.

When administered intramuscularly, the drug is detected in the blood plasma for 4 hours after administration. Tmax is 0.45–0.50 hours. Cmax at doses of 400–500 mg is 3.5–4.0 mcg/ml. Mexiprim® quickly passes from the bloodstream into organs and tissues and is quickly eliminated from the body. The drug retention time (MRT) is 0.7–1.3 hours. Mexiprim® is excreted from the body in the urine, mainly in glucurone-conjugated form and in small quantities unchanged.

Mexiprim® is rapidly absorbed from the gastrointestinal tract with a half-absorption period of 0.08–0.1 hours. Tmax in blood plasma is 0.46–0.5 hours. The Cmax value of Mexiprim® in blood plasma ranges from 50 to 100 ng/ml. T1/2 of Mexiprim® and the average retention time of the drug in the body are 4.7–5 hours and 4.9–5.2 hours, respectively. Mexiprim® is intensively metabolized in the human body with the formation of its glucurone-conjugated product. On average, over 12 hours, 0.3% of the drug is excreted in the urine - unchanged and 50% - in the form of glucuronic conjugate (of the administered dose). Mexiprim® and its glucuronoconjugate are excreted most intensively during the first 4 hours after taking the drug. The urinary excretion rates of Mexiprim® and its conjugated metabolite have significant individual variability.

Indications:

vegetative-vascular dystonia;

anxiety disorders in neurotic and neurosis-like conditions;

relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

— Solution for intravenous and intramuscular administration (optional):

acute cerebrovascular accident;

encephalopathy;

mild cognitive disorders of atherosclerotic origin.

— Tablets (optional):

mild cognitive disorders of various origins (with psychoorganic syndrome and asthenic disorders caused by acute and chronic cerebrovascular accidents, head injury, neuroinfections and intoxications, senile and atrophic processes);

memory disorders and intellectual disability in the elderly;

exposure to extreme (stress) factors.

Contraindications.

increased individual sensitivity to the drug Mexiprim;

acute dysfunction of the liver and kidneys;

childhood;

pregnancy;

breast-feeding.

Dosing.

V/m, IV (stream or drip). Doses are selected individually. When administered by infusion, the drug should be diluted in physiological sodium chloride solution. Begin treatment with a dose of 50–100 mg 1–3 times a day, gradually increasing the dose until a therapeutic effect is obtained. Mexiprim® is administered in a stream slowly over 5–7 minutes, and dropwise at a rate of 40–60 drops per minute. The maximum daily dose does not exceed 800 mg.

For acute cerebrovascular accidents (in complex therapy): in the first 2-4 days - 200-300 mg IV drip once a day, then - 100 mg IM 3 times a day. Duration of treatment is 10–14 days.

For dyscirculatory encephalopathy in the decompensation phase: intravenously in a stream or drip at a dose of 100 mg 2-3 times a day for 14 days. Then the drug is administered intramuscularly at 100 mg/day over the next 2 weeks. For a course of prophylaxis of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 100 mg 2 times a day for 10–14 days.

For mild cognitive impairment in elderly patients and anxiety disorders: the drug is used intramuscularly in a daily dose of 100–300 mg for 14–30 days.

For alcohol withdrawal syndrome: IM in a dose of 100–200 mg 2–3 times a day or IV drip 1–2 times a day for 5–7 days.

For acute intoxication with antipsychotic drugs: IV at a dose of 50–300 mg/day for 7–14 days.

Inside. The therapeutic doses used and the duration of treatment are determined by the sensitivity of patients to the drug. Treatment begins with a dose of 0.25–0.5 g; the average daily dose is 0.25–0.5 g, the maximum is 0.8 g. The daily dose of the drug is distributed into 2–3 doses during the day.

For the treatment of patients with anxiety disorders, vegetative-vascular dysfunctions and cognitive impairment, Mexiprim® is used for 2-6 weeks.

When relieving alcohol withdrawal syndrome, Mexiprim® is used for 5–7 days.

The course of therapy with Mexiprim® is completed gradually, reducing the dose of the drug over 2-3 days.

Side effects: Individual adverse reactions may occur: nausea and dry mouth, drowsiness, allergic reactions.

Overdose.

Symptoms: sleep disturbance (insomnia, in some cases drowsiness).

Treatment: as a rule, not required - symptoms disappear on their own within 24 hours. In severe cases of insomnia, it is recommended to take nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg.

Interaction: Compatible with psychotropic drugs. Enhances the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian drugs (levodopa), reduces the toxic effect of ethyl alcohol.

Special instructions.

The degree of restrictions is determined by individual tolerability of the drug. During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Conditions for dispensing from pharmacies.

On prescription.

Storage conditions.

In a dry place, protected from light,

Mexiprim's analogs

Level 4 ATC code matches:
Trigamma

Riluzole

Huato Boluses

Vitagamma

Vitaxon

Hypoxene

Glycine

Mexidol

Neurox

Glitsed

Cytoflavin

Among the analogues of Mexiprim, the following drugs can be distinguished: Medomexi, 2-ethyl-6-methyl-3-hydroxypyridine succinate, Armadin, 3-hydroxy-6-methyl-2-ethylpyridine succinate, Mexidant, Mexicor, Meksifin, Mexidol, Metostabil, Cerecard , Mexipridol and Ethylmethylhydroxypyridine succinate.

It is worth noting that quite often patients have the question of what is better: Mexiprim or Mexidol ? An unambiguous answer to this question can only be given by the attending physician, who, after a comprehensive medical examination, can correctly prescribe this or that drug, taking into account all the characteristics of a particular patient.

Analogues and other information

There are analogues of the drug Mexiprim based on the active substance. Most often, pharmacies offer Mexidol as a replacement. Which is better, Mexiprim or Mexidol?

These drugs are identical in properties, but the price of Mexidol is higher - 290 rubles for 30 tablets

. Other analogues are given in the table.

In case of an overdose of this drug, sleep disturbances and, less commonly, drowsiness may occur. Usually no treatment is required, the symptoms disappear spontaneously after 1-2 days, but in some cases it is necessary to take sedatives to normalize sleep. The drug may impair the speed of psychomotor reactions, which should be taken into account while working and driving.

Mexiprim price, where to buy

The average price of Mexiprim tablets varies from 140 to 170 rubles.

The price of Mexiprim in ampoules averages 300-330 rubles.

• Online pharmacies in RussiaRussia
• Online pharmacies in UkraineUkraine

ZdravCity

• Mexiprim tablets p.p.o.
  125 mg 30 pcs. ZAO OKFK 156 rub. order
• Mexiprim solution for intravenous and intramuscular injection. 50mg/ml 5ml 5 pcs. LLC NTFF POLYSAN

  360 rub. order

• Mexiprim tablets p.p.o. 125 mg 60 pcs. ZAO OKFK

  330 rub. order

  Read also:  Tetanus vaccination: after it. Symptoms, signs and treatment of the disease, how to get infected
• Mexiprim solution for intravenous and intramuscular injection. 50mg/ml 2ml 10 pcs. FSUE MEZ FSUE/Polisan NTFF

  RUR 347 order

• Mexiprim solution for intravenous and intramuscular injection. 50mg/ml 5ml 15 pcs. LLC NTFF POLYSAN

  976 rub. order

Pharmacy Dialogue

• Mexiprim (tablet p/o 125 mg No. 60) Obninsk Chemical-Pharmaceutical

  RUR 318 order

• Mexiprim (amp. 50 mg/ml 2 ml No. 10) Polisan NTFF

  RUB 331 order

• Mexiprim (tab.p/vol. 125 mg No. 30) Obninsk Chemical-Pharmaceutical

  RUB 158 order

• Mexiprim (amp. 50 mg/ml 2 ml No. 10) Moscow Endocrine Plant

  RUB 334 order

show more

Pharmacy24

• Mexiprim 125 mg No. 30 tablets ZAT "OHFK", Russia
  130 UAH. order
• Mexiprim 50 mg/ml 2 ml No. 10 injection solution TOV "NTFF" Polisan", Russian Federation

  348 UAH order